Yes. FDA recognizes that clinical investigations may be conducted outside of the
U.S., for example, in order to find adequate numbers of subjects for certain
disease states, conditions, or pathogens. The PMA regulation contains information
regarding research conducted outside of the U.S. (21 CFR 814.15). FDA can also
accept data from foreign studies in support of 510(k)s .
